Modality
Multispecific
MOA
CFTRmod
Target
Nectin-4
Pathway
Sphingolipid
ADHD
Development Pipeline
Preclinical
~Mar 2018
→ ~Jun 2019
Phase 1
~Sep 2019
→ ~Dec 2020
Phase 2
Mar 2021
→ Jun 2031
Phase 2Current
NCT03809754
1,693 pts·ADHD
2021-03→2031-06·Not yet recruiting
1,693 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-135.2y awayPh2 Data· ADHD
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Not yet…
Catalysts
Ph2 Data
2031-06-13 · 5.2y away
ADHD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03809754 | Phase 2 | ADHD | Not yet recr... | 1693 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 |